News

NEW AWARD: CONGRATULATIONS, DR. SYLVIE BRETON!

RECIPIENT:  Dr. Sylvie Breton
TITLE: Predicting and Preventing Acute Kidney Injury Associated with Cardiovascular Diseases
TYPE OF AWARD:  PILOT
TECHNOLOGY TYPE: Small Molecule Drug
CLINICAL AREA: Heart
INDICATION: Acute Kidney Injury
INSTITUTION: MGH

DESCRIPTION: One third of cardiac surgery patients and 22% of patients with acute myocardial infarction will develop AKI. AKI diagnosis leads to longer hospital stays and worse outcomes. The current marker used for the detection of AKI is serum creatinine (SCr), but SCr is a lagging prognostic marker. The onset of AKI causes no symptoms, and more than 50% of kidney function has already been lost before SCr levels show a detectable rise. AKI has thus been touted a ‘silent killer’. If diagnosed quickly and treated early, AKI could be prevented. We have recently identified UDP-glucose (UDP-G) as an early biomarker of AKI in ICU patients. Unlike any other AKI biomarker, UDP-G itself causes injury to the kidneys after release by damaged cells. We have demonstrated through a pilot study that UDP-G in ICU patient urine predicts AKI up to 48 hours before SCr and outperforms other AKI biomarkers. However, currently the only method for UDP-G measurement is cumbersome, and not feasible for use in a clinical lab. This proposal involves the development of the first UDP-G assay, which can be performed with equipment available in a clinical lab. The result of this project will be the prototype used for further development toward an FDA approved test for AKI diagnosis.